GTCB's cc have been disappointing in the past so I won't hold my breath waiting for good news. If there is going to be some news, I am hoping it will be related to European ATRYN rights, with Lundbeck/Ovation being the most likely candidate given their rapid movement of ATRYN onto the market in the US.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.